To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Breast cancer, the second leading cause of cancer death of women worldwide, is a heterogenous disease with multiple different subtypes.

She had just shared her exciting pregnancy news on Facebook when a sudden swollen armpit led to a devastating breast cancer diagnosis. Erin Osborne with her children Laila, 3, and Harlyn,10 months, is getting back into fitness to run the 10km in this year’s Australian Running Festival after beating breast cancer.

Those who adhered most closely to a Mediterranean diet rich in plant protein, fish and olive oil were 40 per cent less likely to develop cancer Experts have discovered a Mediterranean diet can cut the risk of a deadly form of breast cancer by 40 per cent. After monitoring 62,000 women over a 20-year period to see how their breast cancer risk was affected by what they ate, scientists found ground-breaking results.

A study published in the International Journal of Cancer on Monday suggests that the Mediterranean diet may reduce the risk of estrogen-receptor-negative breast cancer, a postmenopausal form of the disease with a poor prognosis. The study, which was conducted in the Netherlands, followed 62,573 women ages 55 to 69 who tracked their diets for more than 20 years starting in 1986 as part of a cohort study.

Academics did not see a detrimental effect of soy food intake among women who were treated with endocrine therapy. A iStock Dietary soy products are safe and even beneficial for women diagnosed with breast cancer, according to new research which aimed to help resolve controversy over its link to treatment outcomes.

A Mediterranean diet can reduce the threat of a deadly form of breast cancer by 40pc, a study has found. A typical Mediterranean diet includes high intakes of plant-based proteins such as nuts, lentils and beans, whole grains, fish and ‘healthy’ monounsaturated fats.

IT is devastating to hear that Kadcyla – a crucial life-extending treatment for women with incurable secondary breast cancer – faces being withdrawn from the NHS, following the failure of NICE and the drug’s manufacturer, Roche, to reach an agreement. Kadcyla can offer patients precious extra months – even years – of good quality time with their loved ones, with fewer side effects than other treatments.